Form 4: Immunovant CFO Executes Sell-to-Cover Transaction
Statement of Changes in Beneficial Ownership
Immunovant CFO Tiago Girao sold 25,760 shares of common stock to satisfy tax withholding obligations related to RSU vesting.
Summary
- Tiago Girao, Chief Financial Officer of Immunovant, Inc., sold 25,760 shares of common stock on April 23, 2026.
- The shares were sold at a weighted average price of $29.62 per share, with individual transaction prices ranging from $29.23 to $30.00.
- Following the transaction, the reporting person maintains beneficial ownership of 247,596 shares of common stock.
- The sale was a mandatory 'sell-to-cover' transaction to satisfy tax withholding obligations resulting from the vesting of 52,097 restricted stock units (RSUs).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it is a mandatory administrative action related to tax compliance rather than a discretionary market move.
Positives
- The transaction was non-discretionary and mandated by the company to cover tax liabilities, indicating no change in the executive's long-term outlook on the company.
Negatives
- The transaction resulted in a reduction of the executive's direct equity holdings in the company.
Risks
- None identified; this is a routine administrative transaction related to compensation tax obligations.
Future Outlook
No forward-looking guidance or strategic outlook provided in this filing.
Industry Context
StockSavvy.ai notes that 'sell-to-cover' transactions are standard industry practice for executives receiving equity-based compensation and do not typically signal a change in management sentiment regarding company performance.
Comparison to Industry Standards
- The transaction aligns with standard corporate governance practices for handling tax obligations on vested equity awards in the biotechnology sector.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was non-discretionary and limited to tax coverage.
Key Dates
| Date | Description |
|---|---|
| 04/21/2026 | Vesting date of 52,097 restricted stock units. |
| 04/23/2026 | Date of the reported sell-to-cover transaction. |
| 04/24/2026 | Date of filing the Form 4. |
Keywords
Immunovant, IMVT, Insider Trading, Form 4, CFO, Equity Compensation, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.